Specialty biopharmaceutical group, Ferring Pharmaceuticals, has announced its 30 million CHF investment in its new biotech centre in Switzerland.
Swiss money
The new centre, to be installed at the company’s global headquarters in St Prex, will incorporate discovery and development capabilities for monoclonal antibodies as well as manufacturing capabilities for biologics.
“Ferring is committed to investing in innovative technology platforms to create new solutions for patients in our core areas of reproductive medicine and women’s health, gastroenterology and urology,” explained Michel Pettigrew, president of the executive board and chief operating officer, Ferring Pharmaceuticals. “This significant investment in state-of-the art manufacturing and development technologies fits our strategy to address unmet patient needs in these areas, and will open up additional opportunities for Ferring to help people live better lives.”
In addition to the discovery, development and manufacture of new biologics, the company will also use the new centre to manufacture the active pharmaceutical ingredient of its latest fertility treatment, Rekovelle (follitropin delta).